Gyrodyne, LLC — Q1 2016 Form 10-Q Summary
Business context and reporting period. The unaudited quarter ended March 31, 2016. Following its 2015 merger and completion of the tax liquidation, Gyrodyne reports on a liquidation basis and is pursuing property sales and value-enhancing entitlements before dissolving. Its remaining portfolio included medical-office and industrial properties, principally in New York. The company anticipated completing liquidation during 2018, but said timing could extend.
Financial position and operating metrics
- Net assets in liquidation: $43.57 million at March 31, up $116,427 from $43.46 million at December 31, 2015. Estimated liquidation value was approximately $29.39 per common interest.
- Assets and liabilities: Total assets were $57.08 million, including real estate held for sale of $45.96 million, cash and equivalents of $6.19 million, and marketable securities of $4.89 million. Total liabilities were $13.51 million, including $12.19 million for estimated liquidation and operating costs net of receipts.
- Liquidity and debt: Cash plus marketable securities totaled approximately $11.08 million. No debt balance is separately listed in the statement of net assets; it does list other liabilities and estimated liquidation costs.
- Changes in net assets: The quarter’s $116,427 increase reflected $80,991 of securities value gains, $173,279 of asset-and-liability remeasurement, and a $137,843 reduction in real-estate value.
- Rent and occupancy: Rental revenue was $1.21 million, compared with $1.21 million in the preceding quarter. Overall occupancy was 78%; average effective rent was $19.75 per square foot. Future minimum lease revenues were reported at $7.22 million, with the filing noting property sales affect lease commitments.
- Profit, cash flow and margins: The filing presents liquidation-basis statements of net assets and changes in net assets, not conventional income or cash-flow statements; comparable profit, operating cash flow, and margin figures are therefore not provided.
Material changes and transactions
- One Port Jefferson building sold for $850,000 on January 13, 2016. Two additional Port Jefferson sales, at approximately $900,000 and $820,000, were under contract at quarter-end.
- After quarter-end, Fairfax Medical Center sold on May 4 for an amended price of $14.015 million, down $300,000 from the original agreement. Reported net proceeds were $13.19 million. The company retained a two-year master-lease obligation of approximately $155,000, guaranteed by Gyrodyne, subject to reductions as space is leased.
- In March, the company acquired an adjacent four-acre undeveloped lot for $210,000, including related costs, to support property value enhancement.
- During the quarter, leasing included four new leases and three renewals and two expansions; three leases terminated. Management cited ongoing difficulty maintaining occupancy and rents without tenant incentives.
Outlook, risks and unusual items
- Management estimated a potential $43.6 million cash balance at liquidation, before future distributions, based on assumptions including property sales, operating cash flows, costs and completion by 2018. The estimate excludes potential additional value from entitlement efforts and is not a guaranteed distribution.
- Gyrodyne expects to spend approximately $3.15 million during 2016–2017 on entitlements, zoning and related work for Flowerfield and Cortlandt Manor. It intends to prepare properties for sale rather than develop them, but may consider offers or joint ventures during the process.
- Management said current cash and operating cash flow should fund the liquidation over the next 12 months. It plans to review capital needs at least annually and may distribute excess cash, while first reserving for known and unknown liabilities.
- Key uncertainties include property values and sale timing, entitlement outcomes and costs, tenant vacancies or defaults, financing and real-estate market conditions, and potential claims or liquidation expenses. Management cautioned that estimated asset values, costs and distributions may differ materially from actual results.
- A court approved settlement of the merger-related class action on April 8, 2016, including a $650,000 award for plaintiff’s attorneys’ fees and expenses. The settlement also requires property sales to be arm’s-length and at or above the then-most-recent appraised values.
- The company’s 10.12% interest in Callery Judge Grove had a carrying value of zero; any future proceeds depend on development milestones and were not recognized.
Important facts for investors to verify
- Whether contracted and completed property sales ultimately close at the disclosed prices, and the related net proceeds and retained obligations.
- Whether the $29.39-per-interest estimate and projected $43.6 million liquidation cash balance remain supportable as assumptions and property valuations change.
- Actual entitlement spending, progress and outcomes at Flowerfield and Cortlandt Manor, including whether the work improves eventual sale values.
- Changes in occupancy, lease commitments, tenant incentives and rental receipts, particularly after the Fairfax sale.
- Whether litigation, severance, retention bonuses, taxes and other contingent or liquidation liabilities exceed current estimates, or delay distributions and dissolution.